Da Yang

List of Publications by Year
in descending order

69 papers	27,830 citations	136950 32 h-index	98798 67 g-index
70 all docs	70 docs citations	70 times ranked	45021 citing authors

#	Article	IF	Citations
1	Comprehensive molecular characterization of human colon and rectal cancer. Nature, 2012, 487, 330-337.	27.8	7,168
2	The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genetics, 2013, 45, 1113-1120.	21.4	6,265
3	Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 2014, 513, 202-209.	27.8	5,055
4	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	27.0	2,582
5	Genomic Classification of Cutaneous Melanoma. Cell, 2015, 161, 1681-1696.	28.9	2,562
6	Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 1557.	7.4	466
7	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell, 2018, 33, 706-720.e9.	16.8	400
8	Tumour angiogenesis regulation by the miR-200 family. Nature Communications, 2013, 4, 2427.	12.8	363
9	Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer. Cancer Cell, 2013, 23, 186-199.	16.8	340
10	Plasma miRNAs as Diagnostic and Prognostic Biomarkers for Ovarian Cancer. PLoS ONE, 2013, 8, e77853.	2.5	168
11	Edge-based scoring and searching method for identifying condition-responsive protein protein interaction sub-network. Bioinformatics, 2007, 23, 2121-2128.	4.1	139
12	Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1107-1112.	7.1	137
13	MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nature Communications, 2017, 8, 14634.	12.8	118
14	Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions. Journal of Hematology and Oncology, 2014, 7, 19.	17.0	115
15	<scp>MiR</scp>â€506 suppresses proliferation and induces senescence by directly targeting the <scp>CDK4</scp>/6â€"<scp>FOXM1</scp> axis in ovarian cancer. Journal of Pathology, 2014, 233, 308-318.	4.5	112
16	Apparently low reproducibility of true differential expression discoveries in microarray studies. Bioinformatics, 2008, 24, 2057-2063.	4.1	110
17	Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including <i>VEGFA</i>, in human osteosarcoma. Cancer, 2011, 117, 4925-4938.	4.1	104
18	Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers. Journal of the National Cancer Institute, 2015, 107, .	6.3	102

#	Article	IF	Citations
19	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications, 2016, 7, 11169.	12.8	100
20	HINCUTs in cancer: hypoxia-induced noncoding ultraconserved transcripts. Cell Death and Differentiation, 2013, 20, 1675-1687.	11.2	99
21	Integrated MicroRNA Network Analyses Identify a Poor-Prognosis Subtype of Gastric Cancer Characterized by the miR-200 Family. Clinical Cancer Research, 2014, 20, 878-889.	7.0	97
22	Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene, 2016, 35, 4312-4320.	5.9	83
23	miR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncology Reports, 2014, 31, 2021-2028.	2.6	75
24	Systematic identification of non-coding pharmacogenomic landscape in cancer. Nature Communications, 2018, 9, 3192.	12.8	73
25	Aryl Hydrocarbon Receptor Signaling Prevents Activation of Hepatic Stellate Cells and Liver Fibrogenesis in Mice. Gastroenterology, 2019, 157, 793-806.e14.	1.3	67
26	Differing clinical impact of <i>BRCA1</i> and <i>BRCA2</i> mutations in serous ovarian cancer. Pharmacogenomics, 2012, 13, 1523-1535.	1.3	63
27	The genetic basis for inactivation of Wnt pathway in human osteosarcoma. BMC Cancer, 2014, 14, 450.	2.6	50
28	Gaining confidence in biological interpretation of the microarray data: the functional consistence of the significant GO categories. Bioinformatics, 2008, 24, 265-271.	4.1	49
29	Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma. Cancer Letters, 2010, 291, 31-38.	7.2	49
30	Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance. Acta Pharmaceutica Sinica B, 2020, 10, 105-112.	12.0	49
31	Effects of replacing the unreliable cDNA microarray measurements on the disease classification based on gene expression profiles and functional modules. Bioinformatics, 2006, 22, 2883-2889.	4.1	36
32	An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups. Oncotarget, 2016, 7, 8743-8755.	1.8	36
33	Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in Cancer. Theranostics, 2020, 10, 3939-3951.	10.0	35
34	Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecologic Oncology, 2016, 141, 57-64.	1.4	33
35	Cystathionine β‐synthase regulates mitochondrial morphogenesis in ovarian cancer. FASEB Journal, 2018, 32, 4145-4157.	0.5	33
36	CA-125 Level as a Prognostic Indicator in Type I and Type II Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2013, 23, 815-822.	2.5	32

#	Article	IF	Citations
37	Pregnane X receptor activation potentiates ritonavir hepatotoxicity. Journal of Clinical Investigation, 2019, 129, 2898-2903.	8.2	32
38	<i>ERINA</i> Is an Estrogen-Responsive LncRNA That Drives Breast Cancer through the E2F1/RB1 Pathway. Cancer Research, 2020, 80, 4399-4413.	0.9	31
39	Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer. Scientific Reports, 2019, 9, 12492.	3.3	30
40	Targeted codelivery of doxorubicin and IL-36Î³ expression plasmid for an optimal chemo-gene combination therapy against cancer lung metastasis. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 15, 129-141.	3.3	28
41	LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance. Science Advances, 2021, 7, .	10.3	28
42	Intestinal Sulfation Is Essential to Protect Against Colitis and Colonic Carcinogenesis. Gastroenterology, 2021, 161, 271-286.e11.	1.3	28
43	A rank-based transcriptional signature for predicting relapse risk of stage II colorectal cancer identified with proper data sources. Oncotarget, 2016, 7, 19060-19071.	1.8	27
44	Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer. Chinese Journal of Cancer, 2015, 34, 28-40.	4.9	26
45	MDR1 mediated chemoresistance: BMI1 and TIP60 in action. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2016, 1859, 983-993.	1.9	25
46	The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1. Science Advances, 2021, 7, eabg9241.	10.3	25
47	Genetic variants at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer. International Journal of Oncology, 2011, 38, 1153-61.	3.3	24
48	Finding disease-specific coordinated functions by multi-function genes: Insight into the coordination mechanisms in diseases. Genomics, 2009, 94, 94-100.	2.9	17
49	GO-2D: identifying 2-dimensional cellular-localized functional modules in Gene Ontology. BMC Genomics, 2007, 8, 30.	2.8	15
50	Interrogation of gender disparity uncovers androgen receptor as the transcriptional activator for oncogenic miR-125b in gastric cancer. Cell Death and Disease, 2021, 12, 441.	6.3	15
51	<i><scp>MIIP</scp></i> haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. Journal of Pathology, 2017, 241, 67-79.	4.5	13
52	Systematic Interpretation of Comutated Genes in Large-Scale Cancer Mutation Profiles. Molecular Cancer Therapeutics, 2010, 9, 2186-2195.	4.1	12
53	Origin of mutations in genes associated with human glioblastoma multiform cancer: random polymerase errors versus deamination. Heliyon, 2019, 5, e01265.	3.2	11
54	Targeting metabotropic glutamate receptor 4 for cancer immunotherapy. Science Advances, 2021, 7, eabj4226.	10.3	11

#	Article	IF	Citations
55	Novel glucosylceramide synthase inhibitor based prodrug copolymer micelles for delivery of anticancer agents. Journal of Controlled Release, 2018, 288, 212-226.	9.9	10
56	Translational genomics in cancer research: converting profiles into personalized cancer medicine. Cancer Biology and Medicine, 2013, 10, 214-20.	3.0	10
57	A landscape of synthetic viable interactions in cancer. Briefings in Bioinformatics, 2018, 19, bbw142.	6.5	9
58	MYCâ€binding lncRNA EPIC1 promotes AKTâ€mTORC1 signaling and rapamycin resistance in breast and ovarian cancer. Molecular Carcinogenesis, 2020, 59, 1188-1198.	2.7	7
59	Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer. Cancer Cell, 2013, 23, 705.	16.8	6
60	The regulation of RNA metabolism in hormone signaling and breast cancer. Molecular and Cellular Endocrinology, 2021, 529, 111221.	3.2	6
61	Evaluation of cDNA Microarray Data by Multiple Clones Mapping to the Same Transcript. OMICS A Journal of Integrative Biology, 2009, 13, 493-499.	2.0	4
62	The Adenomatous Polyposis Coli (APC) mutation spectra in different anatomical regions of the large intestine in colorectal cancer. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2018, 810, 1-5.	1.0	4
63	Identifying disease feature genes based on cellular localized gene functional modules and regulation networks. Science Bulletin, 2006, 51, 1848-1856.	1.7	3
64	Viewing cancer genes from co-evolving gene modules. Bioinformatics, 2010, 26, 919-924.	4.1	3
65	Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer. Obstetrical and Gynecological Survey, 2012, 67, 164-165.	0.4	2
66	Characterizing Proteins with Finer Functions: A Case Study for Translational Functions of Yeast Proteins. , 2007, , .		1
67	Finding finer functions for partially characterized proteins by protein-protein interaction networks. Science Bulletin, 2007, 52, 3363-3370.	1.7	1
68	Pitfalls in Experimental Designs for Characterizing the Transcriptional, Methylational and Copy Number Changes of Oncogenes and Tumor Suppressor Genes. PLoS ONE, 2013, 8, e58163.	2.5	1
69	Finding Finer Functions of Cancer Proteins and Rebuilding Cancer-Associated Functional Sub-Networks. International Conference on Bioinformatics and Biomedical Engineering: [proceedings] International Conference on Bioinformatics and Biomedical Engineering, 2010, , .	0.0	0